Skip to content

Cumberland Pharmaceuticals CPIX Proceeds from ATM offering, net

Proceeds from ATM offering, net at other companies

Red Cat Holdings, Inc. logo
Red Cat Holdings, Inc.RCAT
$0
Gryphon Digital Mining, Inc. logo
Gryphon Digital Mining, Inc.ABTC
$110.5M
GTY
Getty RealtyGTY
$19.92M+80.9%
Cineverse Corp. logo
Cineverse Corp.CNVS
$254.5K+2,524%
UMH
UMH PropertiesUMH
$0-100%
Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
$4.76M-77.7%

Other financials

Income statement

See full
Revenue$9.1M-22.0%
Gross profit$7.2M-30.0%
Operating income-$3.1M-342%
Net income-$3.3M-362%
EPS (diluted)-$0.22-375%

Balance sheet

See full
Cash & equivalents$11.0M-27.1%
Total debt$4.8M-7.1%
Total equity$21.6M-24.5%
Total assets$71.0M+1.5%

Cash flow

See full
Operating cash flow$387.0K-90.1%
CapEx--100%
Free cash flow$387.0K-89.9%

Valuation

See full
Market cap$97.09M+138%
Enterprise value$90.91M+207%
P/S2.3×+1.3×

Profitability

See full
Gross margin82.9%-1.4pp
Operating margin-17.2%-125pp
Net margin-17.6%-103pp
FCF margin3.3%

Returns & leverage

See full
Return on equity-29.4%-86.3pp
Debt / equity0.2×0.0×
Current ratio-0.3×

Where this comes from

Reported directly by Cumberland Pharmaceuticals in its filing.

Tagged under the XBRL concept cpix:ProceedsFromATMOfferingNet.

The official record: Cumberland Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cumberland Pharmaceuticals's proceeds from atm offering, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cumberland Pharmaceuticals's proceeds from ATM offering, net?
Cumberland Pharmaceuticals (CPIX) reported proceeds from ATM offering, net of $0 in Q1 2026.
How has Cumberland Pharmaceuticals's proceeds from ATM offering, net changed year-over-year?
Cumberland Pharmaceuticals's proceeds from ATM offering, net increased by 100.0% year-over-year, from -$5.27M to $0.
What does proceeds from ATM offering, net mean?
Represents the net cash proceeds generated from the sale of equity securities through an At-The-Market (ATM) offering program. This metric highlights the company's ability to raise capital incrementally from public markets without a traditional underwritten offering. Investors use this to evaluate dilution risk and the company's strategy for funding growth or operations.